Nuo Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

Nuo Therapeutics, Inc.

Consolidated Balance Sheets

	December 31,	December 31,
	2025	2024
Assets
Current assets
Cash	$548,946	$283,714
Accounts receivable, net	561,667	248,205
Inventory, net	213,761	150,442
Prepaid expenses and other current assets	55,509	159,185
Total current assets	1,379,883	841,546
Property and equipment, net	366,315	177,022
Operating lease right of use assets	99,464	170,940
Total assets	$1,845,662	$1,189,508
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$436,083	$219,190
Accrued expenses	493,792	292,400
Deferred revenues	300,000	-
Current portion of operating lease liabilities	76,410	66,861
Total current liabilities	1,306,285	578,451
Deferred revenue – long term	975,000	-
Note payable	300,000	-
Note payable – related party	200,000	-
Non-current portion of operating lease liabilities	20,936	97,345
Total liabilities	2,802,221	675,796
Commitments and contingencies (Note 10)
Stockholders' Equity (Deficit)
Common stock; $0.0001 par value; 100,000,000 shares authorized; 48,179,039 and 46,816,114 shares issued and outstanding at December 31, 2025 and 2024, respectively	4,818	4,682
Additional paid-in capital	33,810,785	32,768,976
Accumulated deficit	(34,772,162)	(32,259,946)
Total stockholders' equity (deficit)	(956,559)	513,712
Total liabilities and stockholders' equity (deficit)	$1,845,662	$1,189,508

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.